REGENXBIO reported three-year interim data from its Phase II ALTITUDE trial of surabgene lomparvovec, a single-administration gene therapy delivering an anti-VEGF antibody fragment to retinal cells in patients with non-proliferative diabetic retinopathy. Among ten patients at the highest dose reaching the three-year visit, six improved by two or more steps on the Diabetic Retinopathy Severity Scale without additional treatment, and no intraocular inflammation or new safety signals were observed across 17 followed participants. The findings are investigator-reported interim results from a small cohort in an ongoing trial.
Key Points
- Six of ten patients gained two-plus severity steps at year three
- No intraocular inflammation or new safety signals across 17 participants
- Small interim cohort; one case lost to follow-up after supplemental injections
Longevity Analysis
Diabetic retinopathy is the leading cause of vision loss in working-age adults, and the current standard requires indefinite repeat intraocular injections — a treatment burden that drives attrition and allows irreversible damage to accumulate in the retinal microvasculature. Converting a chronic adherence problem into a single procedure addresses the implementation gap that undermines most long-horizon interventions, while early-stage intervention preserves tissue before neovascular changes become permanent. The broader principle holds beyond the eye: protecting small-vessel integrity before structural failure is more tractable than restoring function afterward, and durability of effect matters as much as magnitude.
Original published by Longevity.Technology, by Kyle Umipig.